HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Wenjun Peng Selected Research

pinobanksin

1/2018Galangin and Pinocembrin from Propolis Ameliorate Insulin Resistance in HepG2 Cells via Regulating Akt/mTOR Signaling.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Wenjun Peng Research Topics

Disease

3Neoplasms (Cancer)
01/2021 - 01/2016
2Chronic Obstructive Pulmonary Disease (COPD)
01/2022 - 01/2021
1Glioma (Gliomas)
01/2021
1Respiratory Tract Diseases (Respiratory Tract Disease)
01/2021
1Acute Lung Injury
01/2021
1Carcinoma (Carcinomatosis)
01/2021
1Inflammation (Inflammations)
01/2021
1Adenocarcinoma of Lung
11/2020
1Infections
10/2020
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
03/2020
1Wounds and Injuries (Trauma)
01/2019
1Hypersensitivity (Allergy)
01/2018
1Insulin Resistance
01/2018

Drug/Important Bio-Agent (IBA)

4Proteins (Proteins, Gene)FDA Link
01/2021 - 11/2020
3SmokeIBA
01/2022 - 01/2021
1Biomarkers (Surrogate Marker)IBA
01/2022
1MicroRNAs (MicroRNA)IBA
01/2022
1Particulate MatterIBA
01/2021
1PowdersIBA
01/2021
1Cullin Proteins (Cullins)IBA
01/2021
1Biological ProductsIBA
01/2021
1InterleukinsIBA
01/2021
1Ligases (Synthetase)IBA
01/2021
1Messenger RNA (mRNA)IBA
11/2020
1B7-H1 AntigenIBA
11/2020
1Perilipin-2IBA
10/2020
1ErbB Receptors (EGF Receptor)IBA
03/2020
1Gefitinib (Iressa)FDA Link
03/2020
1Tyrosine Kinase InhibitorsIBA
03/2020
1Phosphotransferases (Kinase)IBA
01/2019
1Janus KinasesIBA
01/2019
1Bee Venoms (Bee Venom)IBA
01/2018
1pinocembrinIBA
01/2018
1pinobanksinIBA
01/2018
1Propolis (Bee Bread)IBA
01/2018
1chrysinIBA
01/2018
1galanginIBA
01/2018
1Caspase 3 (Caspase-3)IBA
01/2016